Recurve Bio

Recurv Pharma is a private U.S. oncology biotech developing RP-001, a novel taxane formulated in a nano-emulsion designed to concentrate drug delivery in tumors while reducing exposure to healthy tissues. The company appears to have been formed as a special-purpose vehicle to advance this single lead asset through clinical proof of concept. Preclinical data described by the company and investors indicate activity across multiple solid tumor models, including drug-resistant settings, and potential combination utility with immune checkpoint inhibitors. As of late March 2026, RP-001 had entered a Phase 1/2a study in patients with advanced malignancies. The requested name "Recurve Bio" does not appear to be the exact commonly used name of this biotech; the closest healthcare match is Recurv Pharma.